{"id":"sirolimus-tacrolimus-mycophenolate-mofetil","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Hyperlipidemia"}]},"_chembl":{"chemblId":"CHEMBL1456","moleculeType":"Small molecule","molecularWeight":"433.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus inhibits mTOR signaling to block T-cell proliferation; tacrolimus inhibits calcineurin to prevent IL-2 production and T-cell activation; mycophenolate mofetil inhibits inosine monophosphate dehydrogenase to selectively suppress lymphocyte proliferation. Together, these agents provide complementary immunosuppression for transplant rejection prevention.","oneSentence":"This triple immunosuppressive regimen inhibits T-cell proliferation and activation through distinct mechanisms to prevent organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:17.717Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention (kidney, heart, liver transplantation)"}]},"trialDetails":[{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT00812786","phase":"PHASE4","title":"Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2007-07","conditions":"Heart Transplant","enrollment":42},{"nctId":"NCT00544115","phase":"PHASE2","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2001-10-16","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":260},{"nctId":"NCT06280950","phase":"PHASE2","title":"Expanding Liver Transplant Immunosuppression Minimization Via Everolimus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-12","conditions":"Liver Transplant","enrollment":340},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT05298358","phase":"PHASE1","title":"RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-18","conditions":"Systemic Sclerosis","enrollment":1},{"nctId":"NCT01363752","phase":"PHASE4","title":"A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-08","conditions":"Kidney Transplantation","enrollment":853},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT06225206","phase":"","title":"Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients","status":"UNKNOWN","sponsor":"Methodist Health System","startDate":"2021-07-01","conditions":"Liver Transplant Failure","enrollment":300},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":"Eye Diseases, Uveitis","enrollment":15},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT00681213","phase":"PHASE4","title":"Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2000-05","conditions":"Adult Primary Kidney Transplantation","enrollment":150},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT04258423","phase":"PHASE3","title":"Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function","status":"TERMINATED","sponsor":"Indiana University","startDate":"2019-12-19","conditions":"Kidney Failure","enrollment":4},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT04415476","phase":"PHASE2","title":"Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-30","conditions":"Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity","enrollment":""},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT02821026","phase":"PHASE1, PHASE2","title":"Omental Islet Transplant","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Type 1 Diabetes","enrollment":4},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT00140543","phase":"PHASE3","title":"European Trial of Immunosuppression in SPK Tx","status":"COMPLETED","sponsor":"EUROSPK Study Group","startDate":"2002-02","conditions":"Diabetes Mellitus, Type 1, Diabetic Nephropathy","enrollment":228},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT03582878","phase":"PHASE4","title":"Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2004-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":238},{"nctId":"NCT01220856","phase":"PHASE2","title":"Reparixin in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2010-07-28","conditions":"Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus","enrollment":9},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT02334488","phase":"PHASE3","title":"Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2014-12-11","conditions":"Chronic Kidney Disease","enrollment":329},{"nctId":"NCT00358657","phase":"PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-05-24","conditions":"Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder","enrollment":14},{"nctId":"NCT03415750","phase":"PHASE4","title":"Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants","status":"COMPLETED","sponsor":"Edoardo Melilli","startDate":"2016-11","conditions":"Hypertrophy, Left Ventricular","enrollment":20},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527},{"nctId":"NCT00713284","phase":"PHASE4","title":"Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic","status":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","startDate":"2007-05","conditions":"Renal Transplantation","enrollment":29},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT01239472","phase":"PHASE4","title":"Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant","status":"COMPLETED","sponsor":"Andre Barreto Pereira","startDate":"2011-01","conditions":"Renal Transplant Rejection, Immunosuppression","enrollment":30},{"nctId":"NCT02954198","phase":"NA","title":"Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2016-12-01","conditions":"Immunosuppression","enrollment":40},{"nctId":"NCT00105001","phase":"PHASE2","title":"Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2004-11","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia","enrollment":210},{"nctId":"NCT01807767","phase":"NA","title":"Myfortic in High MELD Liver Transplantation","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2013-03","conditions":"High Model for End-Stage Liver Disease (MELD) Score","enrollment":""},{"nctId":"NCT02077556","phase":"PHASE4","title":"Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2014-04","conditions":"Drug Interaction Potentiation","enrollment":14},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT01544491","phase":"PHASE3","title":"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08-17","conditions":"Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant","enrollment":106},{"nctId":"NCT01878786","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys","status":"TERMINATED","sponsor":"Matthew Cooper","startDate":"2013-06","conditions":"Delayed Graft Function","enrollment":25},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT00928018","phase":"PHASE3","title":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT01318915","phase":"EARLY_PHASE1","title":"Research Study of ATG and Rituximab in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-07-25","conditions":"Renal Transplant Recipients","enrollment":10},{"nctId":"NCT02096107","phase":"PHASE4","title":"Novartis Everolimus Transition","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2014-02","conditions":"Graft Dysfunction, Interstitial Fibrosis","enrollment":60},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT03596970","phase":"PHASE3","title":"Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT03500848","phase":"PHASE2, PHASE3","title":"Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation","status":"UNKNOWN","sponsor":"Southern Medical University, China","startDate":"2018-05-01","conditions":"Liver Transplantation","enrollment":130},{"nctId":"NCT01649609","phase":"NA","title":"Using mTOR Inhibitors in the Prevention of BK Nephropathy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-03","conditions":"BK Viremia, BK Nephropathy","enrollment":40},{"nctId":"NCT01707849","phase":"PHASE3","title":"The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation","status":"COMPLETED","sponsor":"Hospital Vall d'Hebron","startDate":"2012-10","conditions":"Hepatitis C Recurrence After Liver Transplant","enrollment":18},{"nctId":"NCT01369082","phase":"","title":"Extended Follow-Up After Islet Transplantation in T1D","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-05","conditions":"Type 1 Diabetes (T1D), Islet Transplantation","enrollment":75},{"nctId":"NCT01895049","phase":"PHASE4","title":"Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria","status":"COMPLETED","sponsor":"Helio Tedesco Silva Junior","startDate":"2013-08","conditions":"Kidney Transplantation, Cytomegalovirus","enrollment":171},{"nctId":"NCT01276834","phase":"PHASE4","title":"Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation","status":"TERMINATED","sponsor":"Dianet Dialysis Centers","startDate":"2010-09","conditions":"Renal Transplantation","enrollment":13},{"nctId":"NCT00533442","phase":"PHASE2","title":"Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients","status":"COMPLETED","sponsor":"University of Miami","startDate":"2000-09","conditions":"Type 1 Diabetes","enrollment":170},{"nctId":"NCT00223678","phase":"PHASE4","title":"Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2000-06","conditions":"Kidney Transplant","enrollment":20},{"nctId":"NCT01797315","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"University Hospital of Berlin","startDate":"2007-03","conditions":"Renal Transplant Patients at High-risk for Skin Cancer","enrollment":40},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00240994","phase":"PHASE2","title":"Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression","enrollment":35},{"nctId":"NCT01680861","phase":"PHASE3","title":"Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium","status":"COMPLETED","sponsor":"Gaetano Ciancio","startDate":"2012-11","conditions":"Transplant; Failure, Kidney","enrollment":32},{"nctId":"NCT02671318","phase":"PHASE4","title":"Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence","status":"UNKNOWN","sponsor":"Hospital do Rim e Hipertensão","startDate":"2015-09","conditions":"Cytomegalovirus Infections","enrollment":250},{"nctId":"NCT01964014","phase":"PHASE4","title":"Once-a-day Immunosuppression(CISECON_a_day)","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2013-10","conditions":"Chronic Renal Disease","enrollment":160},{"nctId":"NCT01625377","phase":"PHASE3","title":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Liver Transplantation","enrollment":188},{"nctId":"NCT01005706","phase":"NA","title":"Sirolimus Conversions in African-American Renal Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-08","conditions":"Absence; Kidney","enrollment":40},{"nctId":"NCT01680952","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-09","conditions":"Kidney Transplant Patients","enrollment":158},{"nctId":"NCT02683291","phase":"PHASE4","title":"Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients","status":"COMPLETED","sponsor":"Associação Médico Espírita de Botucatu","startDate":"2014-01","conditions":"Disorder Related to Renal Transplantation, Cytomegalovirus Infections","enrollment":48},{"nctId":"NCT01309022","phase":"","title":"Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Diabetes Mellitus, Type 1","enrollment":""},{"nctId":"NCT02208791","phase":"PHASE4","title":"Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2014-07","conditions":"Kidney Transplantation","enrollment":45},{"nctId":"NCT01631058","phase":"PHASE4","title":"Renal Transplantation in the Elderly - nEverOld Study","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Chronic Renal Failure (CRF), Graft Failure, Transplant; Failure, Kidney","enrollment":90},{"nctId":"NCT01025817","phase":"PHASE3","title":"Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-01","conditions":"Kidney Transplant","enrollment":613},{"nctId":"NCT00166712","phase":"PHASE4","title":"A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2005-04","conditions":"Kidney Transplant Failure and Rejection","enrollment":40},{"nctId":"NCT00693446","phase":"PHASE4","title":"A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids","status":"UNKNOWN","sponsor":"Nantes University Hospital","startDate":"2004-04","conditions":"Pancreas Transplantation, Kidney Transplantation","enrollment":118},{"nctId":"NCT01678937","phase":"","title":"Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-09","conditions":"Liver Transplant Rejection, Immunosuppression","enrollment":31},{"nctId":"NCT01469884","phase":"PHASE4","title":"Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients","status":"COMPLETED","sponsor":"Irmandade Santa Casa de Misericórdia de Porto Alegre","startDate":"2011-11","conditions":"Renal Allograft, Hepatitis C","enrollment":30},{"nctId":"NCT01640743","phase":"NA","title":"Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2010-03","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01354301","phase":"PHASE4","title":"Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2011-05","conditions":"Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection","enrollment":300},{"nctId":"NCT01134952","phase":"PHASE4","title":"Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"London Health Sciences Centre","startDate":"2010-06","conditions":"Hepatitis C","enrollment":11},{"nctId":"NCT00296361","phase":"PHASE3","title":"To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-10","conditions":"Kidney Transplantation","enrollment":634},{"nctId":"NCT00332839","phase":"PHASE4","title":"Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Renal Transplantation","enrollment":93},{"nctId":"NCT00965094","phase":"PHASE4","title":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Renal Failure","enrollment":36},{"nctId":"NCT00811915","phase":"PHASE3","title":"Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2009-01","conditions":"Kidney Transplantation","enrollment":65},{"nctId":"NCT00790439","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07","conditions":"Diabetes Mellitus, Type I","enrollment":""},{"nctId":"NCT00455013","phase":"PHASE2","title":"A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-07","conditions":"Disorder Related to Renal Transplantation","enrollment":93},{"nctId":"NCT02117596","phase":"NA","title":"Calcineurin Inhibitor Based Immunosuppression Withdrawal","status":"COMPLETED","sponsor":"Pediatric Nephrology of Alabama","startDate":"2007-11","conditions":"Renal Transplant","enrollment":52},{"nctId":"NCT01195194","phase":"PHASE4","title":"Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.","status":"COMPLETED","sponsor":"Josep M Grinyo","startDate":"2008-03","conditions":"Disorder Related to Renal Transplantation","enrollment":61},{"nctId":"NCT00311311","phase":"PHASE3","title":"Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-04","conditions":"Atherosclerosis, Kidney Failure","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":81,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"sirolimus, tacrolimus, mycophenolate mofetil","genericName":"sirolimus, tacrolimus, mycophenolate mofetil","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple immunosuppressive regimen inhibits T-cell proliferation and activation through distinct mechanisms to prevent organ rejection. Used for Organ transplant rejection prevention (kidney, heart, liver transplantation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}